Baldwin Wealth Partners LLC MA Sells 5,032 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Baldwin Wealth Partners LLC MA reduced its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 63.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,961 shares of the medical instruments supplier’s stock after selling 5,032 shares during the quarter. Baldwin Wealth Partners LLC MA’s holdings in LeMaitre Vascular were worth $273,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the stock. Canada Pension Plan Investment Board acquired a new position in shares of LeMaitre Vascular during the second quarter valued at about $82,000. Sei Investments Co. raised its holdings in LeMaitre Vascular by 2.0% in the 2nd quarter. Sei Investments Co. now owns 59,211 shares of the medical instruments supplier’s stock valued at $4,872,000 after acquiring an additional 1,140 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of LeMaitre Vascular by 68.6% in the 2nd quarter. AQR Capital Management LLC now owns 22,569 shares of the medical instruments supplier’s stock worth $1,857,000 after acquiring an additional 9,183 shares during the period. The Manufacturers Life Insurance Company grew its holdings in shares of LeMaitre Vascular by 5.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,469 shares of the medical instruments supplier’s stock worth $861,000 after purchasing an additional 583 shares in the last quarter. Finally, Truist Financial Corp grew its holdings in shares of LeMaitre Vascular by 92.1% during the 2nd quarter. Truist Financial Corp now owns 7,054 shares of the medical instruments supplier’s stock worth $580,000 after purchasing an additional 3,381 shares in the last quarter. 84.64% of the stock is owned by institutional investors.

LeMaitre Vascular Trading Up 2.2 %

NASDAQ LMAT opened at $99.06 on Tuesday. LeMaitre Vascular, Inc. has a 1-year low of $56.04 and a 1-year high of $109.58. The company has a 50 day moving average of $97.98 and a 200-day moving average of $92.48. The firm has a market cap of $2.23 billion, a price-to-earnings ratio of 54.13, a PEG ratio of 2.15 and a beta of 0.96.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.05. The firm had revenue of $54.82 million during the quarter, compared to the consensus estimate of $53.50 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business’s revenue for the quarter was up 15.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.33 EPS. On average, analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

Insider Buying and Selling

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of the business’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the completion of the transaction, the director now directly owns 2,278 shares of the company’s stock, valued at approximately $231,148.66. The trade was a 62.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 10.79% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on LMAT. Cantor Fitzgerald assumed coverage on LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 target price for the company. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Oppenheimer reiterated an “outperform” rating and set a $93.00 target price (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Finally, Barrington Research increased their price target on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $94.57.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.